Neurohormonal mechanisms

PreclinicalBiologic

IInstitut National de la Santé Et de la Recherche Médicale, France

Neurohormonal mechanisms is one of 7 biologic programs targeting Apathy. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ApathyActive, not recruiting

ApathyPreclinical

Active, not recruiting

Competition

Competitive Landscape

6 competitors in Apathy

#DrugCompanyPhaseTrials

Neupro

UCB

Approved

1 2

Azilect

Teva

Approved

1 3

Cialis

Eli Lilly

Approved

1 4

Strattera

MMap77

Approved

1 5

Dexedrine Spansule

Innovent Biologics (Suzhou) Co. Ltd.

Approved

1 6

Nourianz

Kyowa Kirin Co., Ltd.

Preclinical

1 7

Neurohormonal mechanisms

IInstitut National de la Santé Et de la Recherche Médicale, France

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Apathy1 trial

Assessment of Apathy in a Real-life Situation, With a Video and Sensors-based System

Completed·IInstitut National de la Santé Et de la Recherche Médicale, France·N/A·NCT03272230·66 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Neurohormonal mechanisms. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Neurohormonal mechanisms compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Neurohormonal mechanisms. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Institut National de la Santé Et de la Recherche Médicale, France company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: IInstitut National de la Santé Et de la Recherche Médicale, France

Neurohormonal mechanisms

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Apathy1 trial

References

Drug Info

Quick Facts

Related News